What is he best known for?
The fields of study he is best known for:
The scientist’s investigation covers issues in Virology, Hepatitis C virus, Sofosbuvir, Hepatitis C and Ribavirin.
His Virology research is multidisciplinary, incorporating elements of Protease and Genotype.
His Hepatitis C virus research incorporates elements of Replicon and Clinical trial.
His Sofosbuvir study incorporates themes from Ledipasvir, Internal medicine, Voxilaprevir and NS5B.
His Internal medicine research includes elements of Gastroenterology and Surgery.
His Ribavirin study combines topics in areas such as Tolerability and Pharmacology.
His most cited work include:
- Ledipasvir and Sofosbuvir for Untreated HCV Genotype 1 Infection (1320 citations)
- Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection (539 citations)
- Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial. (457 citations)
What are the main themes of his work throughout his whole career to date?
His primary areas of study are Virology, Hepatitis C virus, Genotype, Sofosbuvir and Internal medicine.
His study ties his expertise on Replicon together with the subject of Virology.
His Hepatitis C virus research is multidisciplinary, relying on both Hepatitis C, Viral load, Clinical trial and Pharmacology.
His work carried out in the field of Hepatitis C brings together such families of science as Tolerability, Drug resistance and Cohort.
As part of the same scientific family, he usually focuses on Sofosbuvir, concentrating on Ledipasvir and intersecting with Fixed-dose combination and Daclatasvir.
His Internal medicine research incorporates themes from Gastroenterology and Surgery.
He most often published in these fields:
- Virology (64.13%)
- Hepatitis C virus (50.54%)
- Genotype (32.61%)
What were the highlights of his more recent work (between 2016-2021)?
- Virology (64.13%)
- Hepatitis C virus (50.54%)
- Genotype (32.61%)
In recent papers he was focusing on the following fields of study:
His main research concerns Virology, Hepatitis C virus, Genotype, Sofosbuvir and Internal medicine.
His Virology study combines topics from a wide range of disciplines, such as Genotyping and In vitro.
The study incorporates disciplines such as Interferon and Deep sequencing in addition to Hepatitis C virus.
His research integrates issues of NS3 and Viral load in his study of Genotype.
Hongmei Mo combines subjects such as Ledipasvir, Cirrhosis, Regimen and Hepacivirus with his study of Sofosbuvir.
Hongmei Mo has included themes like Gastroenterology and Sofosbuvir/velpatasvir in his Internal medicine study.
Between 2016 and 2021, his most popular works were:
- NS5A resistance-associated substitutions in patients with genotype 1 hepatitis C virus: Prevalence and effect on treatment outcome (145 citations)
- Global epidemiology of HCV subtypes and resistance-associated substitutions evaluated by sequencing-based subtype analyses (88 citations)
- Identification of a Novel Hepatitis C Virus Genotype From Punjab, India: Expanding Classification of Hepatitis C Virus Into 8 Genotypes. (85 citations)
In his most recent research, the most cited papers focused on:
Hongmei Mo mainly investigates Sofosbuvir, Hepatitis C virus, Internal medicine, Ledipasvir and Genotype.
Virology and Ribavirin are closely tied to his Sofosbuvir research.
As a member of one scientific family, he mostly works in the field of Hepatitis C virus, focusing on Discontinuation and, on occasion, Cirrhosis.
In his study, which falls under the umbrella issue of Internal medicine, Viral load is strongly linked to Gastroenterology.
His Ledipasvir study integrates concerns from other disciplines, such as Daclatasvir and Drug resistance.
The Genotype study which covers Clinical trial that intersects with Incidence, Viremia, Virus and Immunology.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
